NEO vs SLNO vs RARE vs ACAD vs JPM

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 2x trailing P/E (54. 2x forward), making it the more compelling value choice. Analysts rate NeoGenomics, Inc. (NEO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 2x versus Soleno Therapeutics, Inc. at 135. 9x. On forward P/E, Soleno Therapeutics, Inc. is actually cheaper at 13. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -76. 3% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: JPM returned +465. 8% versus SLNO's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Ultragenyx Pharmaceutical Inc. 's 1. 43β — meaning RARE is approximately 52% more volatile than JPM relative to the S&P 500. On balance sheet safety, Soleno Therapeutics, Inc. (SLNO) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Soleno Therapeutics, Inc. grew EPS 108. 9% year-over-year, compared to -35. 5% for NeoGenomics, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -79. 5% for RARE. At the gross margin level — before operating expenses — SLNO leads at 98. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Soleno Therapeutics, Inc.

(SLNO) trades at 13. 9x forward P/E versus 61. 9x for NeoGenomics, Inc. — 48. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 98. 6% to $48. 36.

In this comparison, JPM (1.

9% yield) pays a dividend. NEO, SLNO, RARE, ACAD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Both have compounded well over 10 years (JPM: +465. 8%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NEO (Healthcare) and SLNO (Healthcare) and RARE (Healthcare) and ACAD (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NEO is a small-cap quality compounder stock; SLNO is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; ACAD is a small-cap deep-value stock; JPM is a large-cap deep-value stock. JPM pays a dividend while NEO, SLNO, RARE, ACAD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.